A director at Biomerieux sold 5,741 shares at 117.300EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Le scrutin présidentiel US reste incertain, mais le momentum semble être du côté de Donald Trump depuis début octobre : le candidat est désormais en tête dans 6 des 7 swing states, vient de dépasser Kamala Harris dans le vote national et est donné gagnant à 63% chez les parieurs. Nous rappelons les valeurs européennes à privilégier ou à éviter en cas de victoire de Donald Trump, et avons également listé les valeurs européennes ayant une base de production aux US, par nature moins expo...
The outcome of the US presidential election hangs in the balance, but the momentum seems to be with Donald Trump since the beginning of October: the candidate is now in the lead in six of the seven swing states, has just overtaken Kamala Harris in the national vote while 63% of punters are tipping him to win. We recap in the present note on the European stocks to play or avoid in the event of Donald Trump's victory and have also listed European stocks with a production base in the US,...
>Q3 2024: +7.8% with +11% l-f-l. (vs +9.9% in H1) - Q3 sales amounted to € 969m, +7.8% (i.e. +11% l-f-l). At 9M, sales reached € 2,871m (+7.6% and +10.3% l-f-l), impacted by a currency effect of -€ 76m, i.e. -€ 26m in Q3 (vs -€ 44m at the end of June).bioMérieux is maintaining its guidance, namely growth of between 8% and 10% at constant exchange rates. (cons.: € 3,941m +9.2%e – ODDO BHF: +8.5%e), with an expected FX impact of -€ 60m (vs € 70m previously), for an...
>T3 2024: +7,8% avec +11% lfl. (vs +9,9% au S1) - Le CA T3 se monte à 969 M€, +7,8% (soit +11% lfl.). A 9M, les ventes atteignent 2871M€ (+7,6% et +10,3% lfl.), impacté par un effet devises de -76 M€ soit -26 M€ au T3 (vs -44 M€ à fin juin).bioMérieux maintient sa guidance, à savoir une croissance comprise entre 8% et 10% à tcc. (CSS : 3941 M€ +9,2%e – ODDO BHF : +8,5%e), avec un impact FX attendu à -60 M€ (vs 70 M€ précédemment), pour un ROCc. en hausse de 12 % ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.